Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Why Hypersonics Are the Next Big Catalyst for Lockheed Martin Stock

Although the F-35 fighter jet dominates the discussion surrounding LMT stock, the real driving force is Lockheed Martin's hypersonic missile.

10 Blue-Chip Stocks to Buy for the End of the Year

With positive developments in the U.S.-China trade war dialogue, market sentiment has improved significantly. Still, I’d keep my eye on stable blue-chip stocks to buy, just in case.

For the Gambler, GE Stock Looks More Reasonable

For some time, the General Electric stock priced moved largely on emotions. But the company’s Q3 earnings report demonstrated substance regarding the recovery narrative.

3 Charts That Show Bank of America Stock Is Running on Fumes

On the surface, BAC stock looks brilliant thanks to thawing U.S.-China relations. But underneath the surface, the walls are slowly crumbling for Bank of America stock.

Indicators Say Stay on Sidelines When It Comes to eBay Stock

Despite an earnings beat in Q3, the EBAY stock price tumbled after the disclosure. A relationship between the share price and a key metric explains why.

Vale Stock Is Tempting Here, but It Has Too Much Baggage

Since a dam collapse early this year, Vale stock has been under severe pressure. And while the resultant discount may be appealing, its alternatives look like superior bets.

With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback

Teva stock fell sharply this year in large part thanks to the opioid crisis, but with a last-minute deal, shares look more interesting now.

10 Medical Marijuana Stocks to Cure Your Portfolio

Although recreational weed captures headlines, the real money is on broadly accepted medicinal marijuana stocks.

As the Snapchat User Base Ages, Irrelevancy Will Hound SNAP Stock

Snapchat stock was one of the surprise hits of 2019. But whether it can build on that momentum in the years ahead comes down to sustaining its youthful user base into maturity, which is a whole new ballgame.

Amazon Stock Is a Buy, Regardless of Investors’ Timeframes

While Amazon stock may have frustrated investors following Q3, AMZN stock will ultimately move higher based on favorable societal trends.